Autologous T cells expressing a second‐generation anti‐CD19 CAR incorporating the intracellular 4‐1BB costimulatory domain (tisagenlecleucel) have been licensed for the treatment of r/r B‐ALL and aggressive B‐NHL.36, 38. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.